A metastatic breast cancer patient with twice HER2 status changes and BRCA2 secondary mutations: a case report
Breast Communications · 2025
DOI: 10.21037/bc-24-6 ↗Kurz gefasst
Fallbericht in der Zeitschrift Breast Communications, 2025. Verfasst von Yingyun Li und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Categorizing breast cancer into different subtypes could greatly benefit the treatment and thereby improve prognosis. Classification based on expression levels of hormone receptor and human epidermal growth factor receptor 2 (HER2) has been used and proved valuable for many years, which also guided medication effectively in our case. Besides, next-generation sequencing (NGS) may become another considerable reference, complementary to traditional methods. Case Description: We reported a case of a 30-year-old woman with invasive ductal carcinoma accompanied by multiple metastases who underwent several different regimens during disease progression and achieved an overall survival of 13 years. Changes in hormone receptors and HER2 status were detected by immunohistochemistry staining or fluorescence in situ hybridization. NGS revealed BRCA2 germline mutation. Therefore, platinum-based chemotherapy was used and achieved a benefit of 8 months. After chemo-resistance, three secondary BRCA mutations were observed and the patient showed resistance to poly (ADP-ribose) polymerase (PARP) inhibitor treatment.
Conclusions
During the 13-year-long treatment, the medication regimen was changed many times. HER2 expression status changed twice: from negative to positive back to negative, which highlighted the importance of pathology tests of HER2 and hormone receptor throughout the whole duration of treatment. In addition, this study showed that PARP inhibitor failed to recover BRCA2 secondary mutations-mediated platinum-resistance in patients with BRCA2 germline mutation. This representative case may provide insights for treatment decision-making in breast cancer treatment.
Zitieren
APA
Li, Y., Wu, J., Yuan, H., Gao, L., Liu, Y., Shao, X., & Wang, X. (2025). A metastatic breast cancer patient with twice HER2 status changes and BRCA2 secondary mutations: a case report. Breast Communications. https://doi.org/10.21037/bc-24-6
Vancouver
Li Y, Wu J, Yuan H, Gao L, Liu Y, Shao X, et al. A metastatic breast cancer patient with twice HER2 status changes and BRCA2 secondary mutations: a case report. Breast Communications. 2025. doi:10.21037/bc-24-6
BibTeX
@article{Li2025,
author = {Li, Yingyun and Wu, Jiayi and Yuan, Heqing and Gao, Lu and Liu, Yiyuan and Shao, Xiying and Wang, Xiaojia},
title = {A metastatic breast cancer patient with twice HER2 status changes and BRCA2 secondary mutations: a case report},
journal = {Breast Communications},
year = {2025},
doi = {10.21037/bc-24-6}
}
EUVIMED